Diagnostic Accuracy of Plasma p-tau217 as a Pre-Screening Tool for Amyloid-PET: A Decision Curve Analysis in the ADNI Cohort
Journal of Dementia and Alzheimer's Disease · 06.05.2026 · 3 (2) · 22
DOI: 10.3390/jdad3020022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Dementia and Alzheimer's Disease, online erschienen am 06.05.2026. Verfasst von Paolo Ribisi und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer’s Disease Neuroimaging Initiative, DOD ADNI.
Abstract (Originalsprache)
Background/Objectives: Amyloid-PET is accurate but costly and capacity-limited. Blood-based biomarkers (BBMs), particularly plasma p-tau217, offer a scalable alternative for triaging patients. Objective of this study is to evaluate the diagnostic accuracy and clinical utility of plasma p-tau217 as a pre-screening tool for amyloid-PET positivity, identifying operating thresholds for rule-out and rule-in strategies.
Methods
We analyzed 1681 participants from the ADNI cohort with concurrent plasma biomarkers (Fujirebio Lumipulse assays) and 18F-florbetapir PET. The primary outcome was discrimination of amyloid-PET positivity (Centiloid > 20). We compared p-tau217 alone against multivariable models (including Aβ42/40, GFAP, NfL, APOE) using Area Under the Curve (AUC) and Decision Curve Analysis (DCA). Two clinical thresholds were defined: a high-sensitivity “rule-out” cut-off (≥95% sensitivity) and a Youden-optimal “balanced” cut-off. These were validated using stratified bootstrap resampling.
Results
Of 1681 participants, 679 (40.4%) were amyloid-positive. In the full sample, plasma p-tau217 alone achieved an AUC of 0.902 (95% CI 0.885–0.918). Operating thresholds were derived on a development split and applied to an independent validation split (N = 505). In the validation cohort, the high-sensitivity threshold (0.106 pg/mL) yielded 94.6% sensitivity and 93.7% NPV, effectively ruling out amyloid pathology. The Youden threshold (0.177 pg/mL) offered 78.9% sensitivity and 86.0% specificity. DCA demonstrated net benefit for p-tau217 screening over “PET all” strategies across clinically relevant probability ranges.
Conclusions
Plasma p-tau217 provides high discrimination and clinically interpretable operating points for prioritizing confirmatory PET. Implementing a p-tau217-first strategy could significantly reduce unnecessary imaging without compromising diagnostic safety.
Förderung
- Alzheimer’s Disease Neuroimaging Initiative
- DOD ADNI
Zitieren
APA
Ribisi, P., Blandino, V., & Piccoli, T. (2026). Diagnostic Accuracy of Plasma p-tau217 as a Pre-Screening Tool for Amyloid-PET: A Decision Curve Analysis in the ADNI Cohort. Journal of Dementia and Alzheimer's Disease, 3(2), 22. https://doi.org/10.3390/jdad3020022
Vancouver
Ribisi P, Blandino V, Piccoli T. Diagnostic Accuracy of Plasma p-tau217 as a Pre-Screening Tool for Amyloid-PET: A Decision Curve Analysis in the ADNI Cohort. Journal of Dementia and Alzheimer's Disease. 2026;3(2):22. doi:10.3390/jdad3020022
BibTeX
@article{Ribisi2026,
author = {Ribisi, Paolo and Blandino, Valeria and Piccoli, Tommaso},
title = {Diagnostic Accuracy of Plasma p-tau217 as a Pre-Screening Tool for Amyloid-PET: A Decision Curve Analysis in the ADNI Cohort},
journal = {Journal of Dementia and Alzheimer's Disease},
year = {2026},
volume = {3},
number = {2},
pages = {22},
doi = {10.3390/jdad3020022}
}
EUVIMED